Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$53.24 USD

53.24
3,973,139

+2.04 (3.98%)

Updated Jul 25, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&J's Loss in Talc Lawsuits

Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.

Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales

Bristol-Myers' (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over year due to generic erosion for oncology drug Revlimid.

Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal

Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.

Merck (MRK) Beats on Q4 Earnings & Sales, 2023 View Disappoints

Merck (MRK) beats Q4 estimates for earnings and sales. Its 2023 profit guidance disappoints. Stock declines in pre-market.

Is a Surprise Coming for Sanofi (SNY) This Earnings Season?

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Novo Nordisk (NVO) Q4 Earnings Beat Estimates, Revenues Miss

Novo Nordisk (NVO) reports mixed results for Q4 as earnings beat estimates but sales miss on the same. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates

Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.

SNY or NVO: Which Is the Better Value Stock Right Now?

SNY vs. NVO: Which Stock Is the Better Value Option?

GSK's Beats on Q4 Earnings & Sales, Issues Upbeat 2023 Outlook

GSK's (GSK) revenues benefit from strong growth in sales across all segments, especially Shingrix vaccine sales. The company also issues fresh 2023 guidance for all its segments.

Will Keytruda & Gardasil Aid Merck (MRK) Sales in Q4 Earnings?

Merck's (MRK) key products like cancer drug Keytruda and HPV vaccine Gardasil are expected to have driven sales in Q4.

The Zacks Analyst Blog Highlights Expedia, IDEXX Laboratories, Tradeweb Markets, SolarEdge Technologies and Sanofi

Expedia, IDEXX Laboratories, Tradeweb Markets, SolarEdge Technologies and Sanofi are included in this Analyst Blog.

J&J (JNJ) Down as Court Rejects Bankruptcy Claim in Talc Lawsuits

A federal appeals court rejects J&J's (JNJ) efforts to shift over 38,000 lawsuits related to its talcum-based baby powder out of trial courts and into bankruptcy court.

Moderna (MRNA) RSV Jab For Older Adults Gets FDA Breakthrough Tag

Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.

Can Sanofi (SNY) Keep the Beat Streak Alive in Q4 Earnings?

Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.

Nalak Das headshot

Top 5 Nasdaq Composite Stocks to Buy Ahead of Q4 Earnings

Five Nasdaq Composite companies are set to beat earnings estimates. These are: EXPE, IDXX, SNY, TW and SEDG.

Shaun Pruitt headshot

2 Medical Stocks to Consider Buying Before Earnings

There is a continued need for prosperous healthcare companies, here are two medical stocks investors may want to consider buying ahead of earnings this week.

Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?

Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.

Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod

The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).

Merck (MRK) to Report Q4 Earnings: What's in the Cards?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q4 earnings.

Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Sanofi (SNY) closed at $48.49, marking a -0.66% move from the previous day.

Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store?

Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.

Weibo and Viasat have been highlighted as Zacks Bull and Bear of the Day

Weibo and Viasat are part of the Zacks Bull and Bear of the Day article.

Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.

Is a Beat on the Cards for Novo Nordisk (NVO) in Q4 Earnings?

Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the fourth quarter of 2022.

Zacks.com featured highlights include Navios Maritime Partners, Hewlett Packard Enterprise, Aegon, Cowen and Sanofi

Navios Maritime Partners, Hewlett Packard Enterprise, Aegon, Cowen and Sanofi are part of the Zacks Screen of the Week article.